Panelists discuss how differing disease mechanisms, inflammatory drivers, and clinical priorities across AMD, DME, and RVO shape individualized therapeutic goals and the use of newer anti-VEGF agents.
Optimizing Retinal Care with Next-Generation Anti-VEGF Agents: Insights from Clinical Practice
Panelists discuss how key biologic and clinical distinctions—such as ischemia, leakage patterns, and modality-specific insights—guide tailored treatment strategies for BRVO, CRVO, and DME.
Panelists discuss how aflibercept’s structural design and the higher molar dose of its 8-mg formulation enhance VEGF binding, treatment durability, and clinical predictability.
Panelists discuss how faricimab’s dual VEGF-A and Ang-2 inhibition may offer vascular stability advantages over single-pathway blockade, despite ongoing questions about Ang-2’s independent therapeutic impact.
Panelists discuss how higher-dose and dual-pathway anti-VEGF agents enable longer intervals, improved fluid control, and more flexible treatment strategies across retinal vascular diseases.
Panelists discuss how the 8-mg aflibercept formulation improves drying efficacy, extends dosing intervals, and reduces burden while maintaining familiarity for patients across AMD and DME.
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
From bench to bedside: Evolving realities of gene therapy for inherited retinal diseases
2
8 things to know about aflibercept 8 mg for retinal vascular disease
3
Topical liposomal ozonated oil may be a useful treatment in neurotrophic keratopathy
4
Seeing the difference: Multimodal imaging for AMD and GA
5